PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Propranolol Remains Reference Systemic Therapy for Infantile Hemangioma

propranololatenololnadololtimololbeta-blockerscorticosteroidsinfantile hemangiomanetwork meta-analysispediatric dermatologydrug safety Pediatrics

Background Information

Oral propranolol stays first-line for infantile hemangioma.

Infantile hemangioma is a common vascular tumor in infants, and effective management is crucial for reducing complications. Oral propranolol remains the best treatment option for infantile hemangioma with no other interventions showing superior efficacy. Corticosteroids had higher adverse event rates, while atenolol had fewer. Oral propranolol should remain the first-line treatment, but atenolol can be considered for patients intolerant to propranolol. Oral propranolol continues as the reference treatment for infantile hemangioma; atenolol is an alternative for those intolerant to it.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Li C, Yang L, Pan L

Citation: Li C, Yang L, Pan L Efficacy and safety of interventions for infantile hemangioma compared with oral propranolol: an updated systematic review and bayesian network meta-analysis. European journal of pediatrics. 2026;185(8). doi:10.1007/s00431-026-07257-y

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.